Nafamostat for dialysis patients who can't use heparin
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called nafamostat to prevent blood clots during continuous dialysis (CRRT), for people who are at high risk of bleeding or can't take heparin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to be on continuous dialysis (CRRT), or start it within the last 48 hours
- You cannot use standard blood thinner (heparin) or are at high risk for bleeding
- You must weigh at least 110 pounds (50 kg)
- You cannot currently be on any other blood-thinning medicine
- You cannot have active bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to prevent blood clots during kidney dialysis in people with sepsis-related kidney failure. The goal is to see which method is safer and works better to keep the dialysis filter working properly.
This study compares two blood-thinning medications used during continuous dialysis for acute kidney injury: one uses citrate (a chemical that prevents clotting) and the other uses heparin (a standard blood thinner). By looking at how well these treatments work, the study aims to find the safest and most effective way to keep the dialysis filter working.
This trial tests whether a drug called finerenone can help people recover from acute kidney injury (AKI), a sudden loss of kidney function. It might reduce further kidney damage and improve recovery.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
This pilot study tests whether nafamostat is safe for people on hemodialysis who have a high risk of bleeding. It may help clinicians find safer ways to manage blood clotting medicines during dialysis.
This trial is testing a medicine called nafamostat mesylate for people with sepsis (a severe infection) that causes blood clotting problems and who are receiving hemofiltration (a type of blood filtering). The goal is to see if this medicine helps improve their recovery.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.